EB Development to Launch Mandatory Buyout of Eurobio Scientific at €25.30 per Share

Key Facts

1EB Development, the majority shareholder of Eurobio Scientific, announced its intention to file a public buyout offer followed by a squeeze-out.

2The offer price has been set at €25.30 per share in cash for Eurobio Scientific equity.

In a move reflecting the strategic consolidation of key assets by major shareholders, EB Development has announced its intention to launch a mandatory public buyout offer for Eurobio Scientific. According to reports, EB Development, the majority shareholder, plans to follow the offer with a squeeze-out and subsequent delisting of the company. The cash offer price has been set at €25.30 per share for Eurobio Scientific equity.

This initiative stems from EB Development's objective to gain full control of the shares it does not already own, facilitating the company's transition to a private entity. Based on the available facts, this offer provides a definitive cash exit for minority shareholders at a pre-determined price, which typically establishes a floor for the stock. Per market data, such buyout offers often stabilize trading ranges during the transition period.

Based on authoritative data, current price levels for Eurobio Scientific are unavailable at the close of September 16, 2026; however, investors are closely monitoring the offer's execution timeline. In the broader European context, market participants remain focused on the impact of the European Central Bank (ECB) interest rate decision, which was set at 2.65% on September 10, 2024, as financing conditions remain a critical factor for M&A activity.